Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Credit Suisse event now available

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 12, 2021 1:31pm

98 Views

Post# 34120566

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Credit Suisse event now available

THTX cannot change the label for Egrifta which adresses exclusively Lipodystrophy .

But i there are many studies indicatiing that Lipo can be a precursor for Nash.....So why dont physicians use that argument for all Lipo patients .....they can say that this link iis not yet proven but what what have they got to lose......nothing illegal

SPCEO1 wrote: Actually, it is illegal for them to sell Egrifta that way (in a manner it is not approved for). So, while what you are saying is something they no doubt wish they could do (and the patietn would indeed benefit), they can only do so obtusely and that tends not to be very effective.

jeffm34 wrote: If THTX can't convince physicians to prescribe egrifta now to treat and prevent NASH in their HIV patients. (which they could be doing) why would you expect them to do any better in the general population?